Results 101 to 110 of about 21,829 (156)

In vitro susceptibility of Burkholderia cepacia to ceftazidime-avibactam: A systematic review

New Microbes and New Infections
Background: Burkholderia cepacia complex (BCC) is a group of multi-drug resistant (MDR) pathogens that are challenging to treat, especially in cystic fibrosis (CF) patients.
Abolfazl Rafati Zomorodi, Leila Ghanbari_Afra, Hossein Faridafshar, Seyed Nooreddin Faraji, Fatemeh Zarepour, Maryamosadat Mavaei, Mohammad Rahmanian   +6 more
doaj   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae

Antimicrobial Agents and Chemotherapy
Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4
Thomas Lavoie, Teresa Sierra, Katie Daffinee, Jason M. Pogue, Brahim Achour, Kerry LaPlante   +5 more
doaj   +1 more source

Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study [PDF]

Keyang Li,1,* Debao Li,2,* Hongliang Dong,1 Dongmei Ren,2 Dandan Gong,1 Shubo Wang,1 Yang Li,1 Yuanyuan Wu,1 Jikang Yang,3 Wenjuan Yan,4 Yi Li4 1Department of Clinical Pharmacy, Jiaozuo People’s Hospital, Jiaozuo, Henan, People’s Republic of ...
Gong D, Li Y, Yang J, Li D, Dong H, Wang S, Li K, Ren D, Wu Y, Yan W   +9 more
core  

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study [PDF]

Chen-Huan Yu,1 Mao-Song Tsai,2 Chun-Hsing Liao,2 Chia-Jui Yang2 1Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; 2Division of Infectious Disease, Department of Internal Medicine, Far Eastern Memorial Hospital, New
Tsai MS, Yu CH, Yang CJ, Liao CH
core  

Emerging Cross-Resistance to Cefiderocol and Ceftazidime-Avibactam in KPC-Producing <i>Klebsiella pneumoniae</i> During Ceftazidime-Avibactam Therapy. [PDF]

Antibiotics (Basel)
Riazzo C, Elías-López C, Muñoz-Rosa M, Arjona-Torres C, Blanco-Martín T, Machuca I, Torre-Cisneros J, Gracia-Ahufinger I, Kieffer N, Arca-Suárez J, Martínez-Martínez L.   +10 more
europepmc   +1 more source

Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam

, 2019
Objectives: We characterized the first ceftazidime-avibactam-resistant KPC-producing-Klebsiella pneumoniae clinical isolate detected in Greece, before the introduction of ceftazidime-avibactam in clinical practice. Methods: K.
Giamarellou, H., Kontopoulou, K., Antoniadou, A., Souli, M., Galani, I., Karaiskos, I.   +5 more
core   +1 more source

Ceftazidime-avibactam in elastomeric pump for vascular graft infection: a case report. [PDF]

Infez Med
Berruti M, Pincino R, Laurenda D, Sciolè K, Migliorati M, Forni N, Malerba G, Farinella ST, Casella L, Cenderello G.   +9 more
europepmc   +1 more source

Severe hypokalemia induced by ceftazidime-avibactam: Case report. [PDF]

Medicine (Baltimore)
Yuan Y, Gu Y, Bai W, Liu W, Li W, Yin Y.
europepmc   +1 more source